Antibody-Drug Conjugates


ADCs: Global service demand buoyed by approvals, WuXi

By Dan Stanton

Antibody-drug conjugates (ADCs) are one of the “hottest areas of research” says STA Pharmaceutical and WuXi Biologics which are investing in conjugation and fill/finish capabilities in China.


Daiichi Sankyo inks Glycotope ADC deal

By Flora Southey

Daiichi Sankyo Company has signed an option agreement to develop Glycotope’s antibody drug conjugate (ADC) to target various cancers including ovarian, lung and breast tumours.

Sharma plans to add to the company's acquisitions

CPhI Worldwide 2015

Profile of a CEO: Piramal Chief shares M&A plans

By Fiona BARRY

Piramal chief executive Vivek Sharma won last week’s CPhI award for the pharma industry’s CEO of the year. spoke to Sharma about his plans for the CDMO the day after the jury’s unanimous decision.

Piramal acquires Kentucky-based CDMO for $30m

Piramal acquires Kentucky-based CDMO for $30m

By Zachary Brennan

India-based CMO Piramal has acquired US-based sterile injectable CDMO (contract development and manufacturing organization) Coldstream Laboratories for $30.65m.